Bob Iger’s stunning return as Disney CEO throws all of Bob Chapek’s major decisions into question

Bob Iger’s stunning return as Disney CEO throws all of Bob Chapek’s major decisions into question


Robert Iger, Chairman and CEO at The Walt Disney Company speaks in Laguna Beach, California, October 22, 2019.

Mike Blake | Reuters

Bob Iger’s shocking return as Disney‘s chief executive officer immediately throws into question several major decisions made by outgoing CEO Bob Chapek.

Disney shares have fallen more than 40% this year, including slumping on weak fiscal fourth-quarter results earlier this month. The Disney board’s choice to replace Chapek with Iger speaks to it having more confidence Iger will deliver better results. Iger has disapproved of several of Chapek’s changes to Disney despite handpicking him as his successor in early 2020, according to people familiar with the matter, as CNBC reported earlier this year.

The biggest point of contention may be Chapek’s reorganization of the company, which established a new division called Disney Media and Entertainment, or DMED, and consolidated budgetary power for Disney’s content and distribution divisions under Kareem Daniel. Undoing a complete restructure of a company would be messy and time consuming, but it’s hard to imagine Iger will keep Chapek’s organization in place. Daniel’s position at the company also becomes more tenuous. He has close connections to Chapek.

Iger also believed Disney+ should underprice competitive streaming services to maximize its price-value perception among consumers. Chapek decided to raise Disney+’s price to $10.99 without ads as of Dec. 8, making it more expensive than other no-ad streaming services, such as Paramount+ and NBCUniversal’s Peacock. Given Dec. 8 is just weeks away, it may be too late for Iger to walk back that price increase — or the decision to price Disney+ with ads at $7.99 per month rather than a lower price — but it’s possible.

The two leaders don’t disagree on everything. Both have long championed the value of ESPN and Hulu, which are both majority controlled by Disney. Disney has the option to buy Comcast’s 33% in Hulu in January 2024. Chapek expressed a desire to move forward with that transaction. Given Iger’s support for a three-pronged streaming strategy of Hulu, ESPN+ and Disney+, it’s likely he would choose to do the same.

But Iger clashed with Chapek’s initial handling of how Disney reacted to Florida’s controversial “Don’t Say Gay” legislation, privately expressing angst about how the Disney brand may be affected. It wouldn’t be surprising if Iger’s first order of business, before unwinding any of Chapek’s structural changes or reeling in direct-to-consumer spending, is to bring a sense of pride back to the company’s culture.

WATCH: Bob Chapek and Bob Iger’s strained relationship

'Extremely awkward': Inside the rift between Disney's Chapek and Iger



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More